Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

Clinical Therapeutics

Volumn 29, Issue 3, 2007, Pages 450-463

  Biederman, Joseph ^a   Krishnan, Suma ^b   Zhang, Yuxin ^c   McGough, James J ^d   Findling, Robert L ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b New River Pharmaceuticals   (United States)

^c Xtiers Consulting   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

attention deficit hyperactivity disorder; lisdexamfetamine; NRP 104; stimulant

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DEXTROAMPHETAMINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYSINE; MALE; TREATMENT OUTCOME;

EID: 34247257281     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(07)80083-X     Document Type: Article

References (31)

1. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry 2 (2003) 104-113
2. Greenhill L.L., Pliszka S., Dulcan M.K., et al., American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 Suppl 2 (2002) 26S-49S
3. Stein M., and Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contemp Pediatr. 20 (2003) 83-110
4. Brown R.T., Amler R.W., Freeman W.S., et al., American Academy of Pediatrics Committee on Quality Improvement and the American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics 115 (2005) e749-e757
5. Rappley M.D. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med. 352 (2005) 165-173
6. Jadad A.R., Boyle M., Cunningham C., et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 11 (1999) i-viii
7. Jadad A.R., Boyle M., Cunningham C., et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 11 (1999) 1-341
8. Llana M.E., and Crismon M.L. Methylphenidate: Increased abuse or appropriate use?. J Am Pharm Assoc (Wash) 39 (1999) 526-530
9. McCabe S.E., Teter C.J., Boyd C.J., and Guthrie S.K. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health 35 (2004) 501-504
10. Wolraich M.L., Wibbelsman C.J., Brown T.E., et al. Attentiondeficit/hyperactivity disorder among adolescents: A review of the diagnosis, treatment, and clinical implications. Pediatrics 115 (2005) 1734-1746
11. Stockl K.M., Hughes T.E., Jarrar M.A., et al. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm. 9 (2003) 416-423
12. Stryer L. Biochemistry (1995), WH Freeman & Co
13. Vyvanse™ (risdexamfetamine dimesylate). Wayne, Pa: Shire Pharmaceuticals. New drug application.
14. Boca Raton, Fla. Boyle L., Moncrief S., and Krishnan S. Pharmacokinetics of NRP104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous or oral dose in rats. Paper presented at: 46th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting (June 12-15, 2006)
15. Krishnan S. Toxicity profile of lisdexamfetamine dimesylate (LDX, NRP104) in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol. In press.
16. Toronto, Ontario, Canada. Biederman J., Boellner S.W., Childress A., et al. Improvements in symptoms of attention-deficit/hyperactivity disorder in school-aged children with lisdexamfetamine (NRP104) and mixed amphetamine salts, extendedrelease versus placebo. Poster presented at: Annual Meeting of the American Psychiatric Association (May 24, 2006)
17. Available at:. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Accessed February 22 (2002-2007), WHO, Geneva, Switzerland. http://www.emea.eu.int
18. and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Accessed February 22, 2007. Adopted by the 18th WMA General Assembly. Helsinki, Finland, June 1964 (2000). http://www.wma.net/e/policy/b3.htm Accessed February 22, 2007
19. American Psychiatric Association. Task Force on DSM-1V. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IVTR) (2000), American Psychiatric Association, Washington, DC
20. DuPaul G.J., Power T.J., Anastopoulos A.D., et al. ADHD Rating Scale-IV:Checklists, Norms, and Clinical Interpretation (1998), Guilford Press, New York, NY
21. Faries D.E., Yalcin I., Harder D., and Heiligenstein J.H. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 5 (2001) 107-115
22. Kaufman J., Birmaher B., Brent D., et al. Kiddie-SADS Present and Lifetime Version Diagnostic Interview version 1.0 (1996), Rao & Ryan, Kaufman, Birmaher, Brent
23. Conners C.K., Sitarenios G., Parker J.D., and Epstein J.N. The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 26 (1998) 257-268
24. DHEW Publication 76-338. Guy W. Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology (1976), US Dept of Health, Education, and Welfare, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, Md 218-222
25. Medical Dictionary for Regulatory Activities [MedDRA Web site] (2007). http://www.meddramsso.com/MSSOWeb/index.htm
26. Weiss M.D., Gadow K., and Wasdell M.B. Effectiveness outcomes in attention deficit/hyperactivity disorder. J Clin Psychiatry. 67 Suppl 8 (2006) 38-45
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed (1988), Lawrence Erlbaum Associates, Hillsdale, NJ
28. Biederman J., Lopez F.A., Boellner S.W., and Chandler M.C. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 110 (2002) 258-266
29. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Com mittee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108 (2001) 1033-1044
30. Steinhoff K.W. Attention-deficit/hyperactivity disorder: Medication treatment-dosing and duration of action. Am J Manag Care. 10 Suppl 4 (2004) S99-S106
31. Biederman J., Faraone S.V., Monuteaux M.C., and Grossbard J.R. How informative are parent reports of attention deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics 113 (2004) 1667-1671